A Case of Persistent SARS-CoV-2 PCR Positive after Chemotherapy for B-cell Lymphoma

Hisanori Hirokawa; Hirokuni Hirata; Ryo Kitajima; Masahira Irokawa; Tomoyuki Ishiguro; Tomoki Hasegawa; Junya Sato; Atsutaka Ozaki; Masafumi Arima; Shinji Teramoto; Kosuke Haruki; Takamitsu Okamura; Hideto Tamura; Koshi Hashimoto; Yasutsugu Fukushima

doi:10.51040/dkmj.1.2_141

Case Reports

A Case of Persistent SARS-CoV-2 PCR Positive after Chemotherapy for B-cell Lymphoma

Hisanori Hirokawa, Hirokuni Hirata, Ryo Kitajima, Masahira Irokawa, Tomoyuki Ishiguro, Tomoki Hasegawa, Junya Sato, Atsutaka Ozaki, Masafumi Arima, Shinji Teramoto, Kosuke Haruki, Takamitsu Okamura, Hideto Tamura, Koshi Hashimoto, Yasutsugu Fukushima

Author information

Hisanori Hirokawa
Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center
Hirokuni Hirata
Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center
Ryo Kitajima
Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center
Masahira Irokawa
Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center
Tomoyuki Ishiguro
Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center
Tomoki Hasegawa
Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center
Junya Sato
Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center
Atsutaka Ozaki
Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center
Masafumi Arima
Department of Rheumatology, School of Medicine, Dokkyo Medical University, Tochigi, Japan
Shinji Teramoto
Department of Respiratory Medicine, Tokyo Medical University Hachioji Medical Center
Kosuke Haruki
Department of Laboratory Medicine, Dokkyo Medical University, Saitama Medical Center
Takamitsu Okamura
Department of Diabetes, Endocrinology and Hematology, Dokkyo Medical University, Saitama Medical Center
Hideto Tamura
Department of Diabetes, Endocrinology and Hematology, Dokkyo Medical University, Saitama Medical Center
Koshi Hashimoto
Department of Diabetes, Endocrinology and Hematology, Dokkyo Medical University, Saitama Medical Center
Yasutsugu Fukushima
Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University, Saitama Medical Center

Keywords: B-cell lymphoma, chemotherapy, SARS-CoV-2, pneumonia, antibody cocktail, immunocompromised host

JOURNAL OPEN ACCESS

2022 Volume 1 Issue 2 Pages 141-146

DOI https://doi.org/10.51040/dkmj.1.2_141

Details

Abstract

The patient was a 68-year-old woman who was hospitalized for SARS-CoV-2 pneumonia while receiving chemotherapy for B-cell lymphoma. She experienced repeated episodes of pneumonia that temporarily went into remission with steroid and remdesivir and but then relapsed or worsened. However, no particular subjective symptoms or deterioration on imaging was observed by an antibody cocktail treatment after Day 119. SARS-CoV-2 IgM and IgG antibody levels were below the limit of detection on Day 180 but she tested positive for SARS-CoV-2 by PCR on Day 151. In the case of this patient who had persistent SARS-CoV-2 infection due to being immunocompromised, treatment temporarily stalled the worsening of symptoms. However, new treatments for such patients should be established soon.

Corresponding author

Register with J-STAGE for free!